<DOC>
	<DOCNO>NCT01268800</DOCNO>
	<brief_summary>Personalization AML therapy , require reliable mechanism accurate characterization patient specific leukemia phenotype genotype . Patient 's specific leukemic phenotype practical clinical term , patient 's leukemia sensitivity induction therapy , best investigate in-vivo induction . Elimination circulate leukemic blast peripheral blood day 5 show discriminate good responder superior long term survival poor responder poor outcome . However , many AML patient circulate blast diagnosis even , elimination rate peripheral blood never correlate actual response bone marrow . Currently , available source patient 's specific leukemia profile , bone marrow sample diagnosis . Since leukemic blast heterogeneous come multiple different clone , `` diagnosis '' marrow consist spectrum chemotherapy sensitive resistance clone . Clones may vary molecular abnormality result `` diagnosis '' marrow may overlook minor resistant exist clone . Long term prognosis determine resistant clone though interest focus abnormality clone . Residual blast day 5 marrow may better represent profile patient 's leukemic resistant clone .</brief_summary>
	<brief_title>Rapid Profiling Bone Marrow , Presentation After 5 Days Induction Therapy</brief_title>
	<detailed_description />
	<criteria>Diagnosis acute myeloid leukemia APL Age &gt; 18 Patient 's consider physician `` fit '' intensive induction therapy Withdrawal inform consent inability consent Previous allogeneic transplantation . One follow lab value persistent presentation day 5 : Serum creatinine &gt; 2mg/dl , Direct bilirubin &gt; 2mg/dl SGOT ( AST ) &gt; x4 upper limit normal Left ventricular ejection fraction &lt; 40 % assess 2D echocardiogram Coagulation abnormality ( INR &gt; 1.6 , PTT &gt; x1.5 normal range )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>Induction</keyword>
</DOC>